NAS:HRTS

Tema GLP-1 Obesity & Cardiometabolic ETF

$ 33.52 0.18 ( +0.54%) 04:00 PM EST
PE Ratio:
37.22
PB Ratio:
5.62
Volume:
9.32K
Dividend Yield %:
0
Last Holding update 2024-10-21 44 Stocks (5 new)
Value $87.00 Mil Turnover 27 %
Top Holdings: AMGN(7.18%) LLY(5.59%) ALNY(5.37%) VRTX(4.50%) OCSE:NOVO B(4.49%)
Portfolio Report
Registrant: Tema GLP-1, Obesity & Cardiometabolic ETF
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Performance Chart Fundamental Charts Technical Indicators Gurus Trades Top Holdings Sector Breakdowns Holding History Back to Top

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Key Statistics

Name Value
Day's Open ($) 33.45
Day's Range ($) 33.45 - 33.79
Day's Volume 9,320
52-Week Range ($) 26.26 - 36.03
Beta -
Volatility -
14-Day RSI 45.2
14-Day ATR ($) 0.417728
20-Day SMA ($) 33.6055

Fundamental Data

Name Value
Market Cap (Mil $) 83.13
Shares Outstanding (Mil) 2.48
PE Ratio 37.22
PE Ratio (10y Range) 37.15 - 37.22
PE Ratio (10y Median) 37.22
PB Ratio 5.62
PB Ratio (10y Range) 5.29 - 5.62
PB Ratio (10y Median) 5.62

Dividend Data

Name Value
Dividends per Share (TTM) ($) -
Dividend Yield % -
Dividend Yield % (10y Range) -
Dividend Yield % (10y Median) -
Next Dividend Payment Date
Dividend Frequency -

HRTS Tema GLP-1 Obesity & Cardiometabolic ETF Fundamental Charts

Historical TTM Price-to-Earnings for HRTS Tema GLP-1 Obesity & Cardiometabolic ETF

Historical TTM Price-to-Earnings without NRI for HRTS Tema GLP-1 Obesity & Cardiometabolic ETF

Historical Price-to-Book Ratio for HRTS Tema GLP-1 Obesity & Cardiometabolic ETF

Historical Dividend Yields for HRTS Tema GLP-1 Obesity & Cardiometabolic ETF

HRTS Tema GLP-1 Obesity & Cardiometabolic ETF Technical Indicators

Moving Average

Momentum

Gurus Latest Trades with NAS:HRTS

No Available Data

NAS:HRTS is held by these investors

No Available Data
Tema GLP-1, Obesity & Cardiome... Top Holdings of 2024-08-31 View Full List
Ticker
Company
Shares
Value ($1000)
Shares Change %
Weighting %
Trade Impact %
% of Shares outstanding
3M Change %
YTD Change %
Market Cap $Mil
Industry
AMGN 		Amgen Inc
18,656
6227.930
+58.65%
7.180
+2.65%
0.000
-4.62%
+12.55%
170424.709
Drug Manufacturers
LLY 		Eli Lilly and Co
5,053
4850.980
+20.00%
5.590
+0.93%
0.000
+11.46%
+54.39%
806412.323
Drug Manufacturers
ALNY 		Alnylam Pharmaceuticals Inc
17,730
4657.490
+48.33%
5.370
+1.75%
0.010
+22.17%
+49.89%
36833.653
Biotechnology
VRTX 		Vertex Pharmaceuticals Inc
7,875
3905.130
-9.32%
4.500
-0.58%
0.000
-3.81%
+17.08%
122952.146
Biotechnology
OCSE:NOVO B 		Novo Nordisk AS
28,003
3892.890
+14.68%
4.490
+0.57%
0.000
-11.46%
+11.61%
3429227.195
Drug Manufacturers
BBIO 		BridgeBio Pharma Inc
128,429
3576.750
+100.92%
4.120
+2.07%
0.070
-9.65%
-39.46%
4595.520
Biotechnology
TSE:4519 		Chugai Pharmaceutical Co Ltd
64,989
3282.570
+22.06%
3.790
+0.68%
0.000
+25.40%
+48.09%
12925513.515
Drug Manufacturers
RARE 		Ultragenyx Pharmaceutical Inc
53,648
3046.130
+22.00%
3.510
+0.63%
0.060
+18.30%
+10.98%
4891.207
Biotechnology
CYTK 		Cytokinetics Inc
51,073
2915.250
+76.13%
3.360
+1.45%
0.040
-12.45%
-37.41%
6148.890
Biotechnology
LSE:AZN 		AstraZeneca PLC
15,827
2759.080
New Holding
3.180
+3.18%
0.000
-3.17%
+11.89%
180268.263
Drug Manufacturers

Tema GLP-1, Obesity & Cardiometabolic ETF's Historical Top Holdings Breakdowns

Tema GLP-1, Obesity & Cardiometabolic ETF's Top Stock Picks View Full List
Ticker
Company
Date
Action
Impact %
Price Range
Price
Price Change from Avrg%
Comment
Current Shares
Share Change
LSE:AZN 		AstraZeneca PLC2024-08-31New Buy
+3.18%
●
119.44 (£124.93) 132.74
£116.28
-6.92%
New holding
15,827
15,827
AMGN 		Amgen Inc2024-08-31Add
+2.65%
●
298.5 ($320.7) 335.97
$317.17
-1.10%
Add 58.65%
18,656
6,897
BBIO 		BridgeBio Pharma Inc2024-08-31Add
+2.07%
●
23 ($26.09) 29.25
$24.44
-6.32%
Add 100.92%
128,429
64,507
BMY 		Bristol-Myers Squibb Co2024-08-31Sold Out
-2.05%
●
39.66 ($44.46) 50.45
$52.64
18.40%
Sold Out
0
-31,703
NARI 		Inari Medical Inc2024-08-31Reduce
-1.93%
●
43.04 ($49.11) 58.62
$42.56
-13.34%
Reduce -60.59%
15,942
-24,509
CRBP 		Corbus Pharmaceuticals Holdings Inc2024-08-31New Buy
+1.86%
●
42.48 ($52.71) 61.55
$16.34
-69.00%
New holding
26,295
26,295
OMCL 		Omnicell Inc2024-08-31Sold Out
-1.80%
●
25.61 ($32.98) 45.43
$40.39
22.47%
Sold Out
0
-35,000
ALNY 		Alnylam Pharmaceuticals Inc2024-08-31Add
+1.75%
●
149.3 ($233.77) 287.01
$286.91
22.73%
Add 48.33%
17,730
5,777
CYTK 		Cytokinetics Inc2024-08-31Add
+1.45%
●
48.41 ($55.29) 60.16
$52.26
-5.48%
Add 76.13%
51,073
22,075
XSWX:NOVN 		Novartis AG2024-08-31Reduce
-1.31%
●
92.73 (CHF96.94) 102.12
CHF99.81
2.96%
Reduce -45.18%
9,760
-8,044

Tema GLP-1, Obesity & Cardiometabolic ETF Total Holding History ($B)

To

Tema GLP-1, Obesity & Cardiometabolic ETF's Asset Allocation

To

Tema GLP-1, Obesity & Cardiometabolic ETF Past Portfolios

Portfolio Date Number of Stocks New Stocks Total Value ($Mil) Q/Q Turnover

Top Ranked Articles

  • 1

Tema GLP-1, Obesity & Cardiometabolic ETF's Hypothetical Growth since 2024-08-31

Tema GLP-1, Obesity & Cardiometabolic ETF's Yearly Returns

Year Portfolio % % Excess Gain %

Tema GLP-1, Obesity & Cardiometabolic ETF's Holdings Heat Map

Size field:

Tema GLP-1, Obesity & Cardiometabolic ETF's Holdings Bubble Chart

Tema GLP-1, Obesity & Cardiometabolic ETF News

  • 1

Discussions on Tema GLP-1 Obesity & Cardiometabolic ETF

User's Avatar
How would you rate this stock? HRTS
No discussions yet.
Research Tools
All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board
Product
Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文
Education
Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation
Company
About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program
Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey
Follow Us
download GuruFocus on Apple store download GuruFocus on Google Play
Disclaimers
GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.
© 2004-2024 GuruFocus.com, LLC. All Rights Reserved.